A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety.

"structure information will be released from the protein data bank (pdb id 7wn8) upon publication of this manuscript. availability of data and materials all relevant data are included in this manuscript and its supplementary information files. structure information will be released from the protein data bank (pdb id 7wn8"

"Declarations Ethics approval and consent to participateHuman PBMCs were purchased from Shanghai Aoneng Biotechnology Co., Ltd. The use of these samples was approved by the IRB of NIBS. All animal studies were conducted following the National Guidelines for the Housing and Care of Laboratory Animals in China and performed under approved Institutional Animal Care and Use Committee (IACUC) protocols at the National Institute of Biological Sciences, Beijing. Consent for publicationNot applicable. Competing interestsYL, JL, and JS are inventors of a patent application regarding the pH-dependent antibodies. Other authors declare no conflict of interest. Competing interests YL, JL, and JS are inventors of a patent application regarding the pH-dependent antibodies. Other authors declare no conflict of interest."

"Funding This work was supported by grants from the Ministry of Science and Technology of the People's Republic of China (973 program #2012CB837600 to JS), Beijing Municipal Science and Technology Commission, and Beijing Key Laboratory of Pathogen Invasion and Immune Defense (Z171100002217064 to JS)."